Phase ll trial of TS-1 + CDDP + Trastuzumab (SPT) - 3 weekly schedule in HER2-positive advanced gastric cancer without measurable metastatic lesion (HERBIS-1B) (OGSG 1202)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2016
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Trastuzumab
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms HERBIS-1B
- 19 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Nov 2015 Planned End Date changed from 21 Feb 2019 to 31 May 2018 as reported by University Hospital Medical Information Network - Japan record.
- 16 Nov 2014 Planned End Date changed from 21 Feb 2017 to 21 Feb 2019 as reported by University Hospital Medical Information Network - Japan record.